U.K. trails EU neighbors in insulin pump use, report shows; FDA approves oral brain hemorrhage drug;

> A recent report found that the U.K. trails nearby countries such as Germany and Norway in the use of insulin pumps, with only 7% of Type 1 diabetes patients using them. In those countries, about 15% of patients use the delivery devices, and 40% in the U.S. opt for a pump, according to the report. Story

> The FDA approved Arbor Pharmaceuticals' Nymalize, the first nimodipine oral solution for brain hemorrhage patients. It was previously available as a liquid-filled gel capsule. Report

> Korean researchers have developed a new nanoparticle contrast medium to diagnose cancer that releases an anti-cancer drug and targets the tumor on-site. In mice, tumors shrunk 90% in 48 hours. Story

> Scientists at the Indian Institute of Science in Bangalore have created a needleless vaccine delivery system that uses supersonic shock waves to innoculate patients painlessly. Article

> Halo Pharma and Altus Forumulation have joined forces to create a series of drugs based on Altus' drug delivery technologies that include high-dose delivery, taste-masked controlled release liquids and tamper- and abuse- resistant medicines. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.